JCEM:胎儿接触大麻和儿童代谢结果

2022-04-27 从医路漫漫 MedSci原创

大麻使用者所生的新生儿更有可能出现宫内生长受限和低出生体重。

背景:美国孕妇使用大麻的人数正在上升。在2002年至2017年期间,自我报告的使用增加了一倍多(从3.4%增加到7.0%)。然而,自我报告可能会低估实际使用情况。2016年在科罗拉多州进行的一项研究显示,22.4%的孕妇在脐带组织中检测到了羧基化形式的δ9-四氢大麻酚(THC-COOH),而只有2.6%的孕妇自称使用过。

孕妇越来越多地使用大麻并非没有风险。大麻使用者所生的新生儿更有可能出现宫内生长受限和低出生体重。生长受限的后代可能会经历过度的出生后追赶生长,这种模式与晚年患肥胖症、代谢综合征和2型糖尿病病的风险增加有关。然而,胎儿接触大麻对后代代谢结果的潜在影响知之甚少。Gillies及其同事最近的一项研究表明,在雌性Wistar大鼠后代中,胎儿暴露于THC与β细胞质量减少和葡萄糖不耐受有关。在一项基于大规模人群的队列研究中,CajachaguaTorres及其同事观察到,自我报告的母亲或父亲在怀孕期间使用大麻与10岁子女中较高的体重指数(身体质量指数)有关。然而,他们报告说这与非空腹血糖水平无关。鉴于数据的缺乏,有必要进一步研究这个新颖的研究问题,尤其是在幼儿期。

目的:评估胎儿暴露于大麻对早期生活中肥胖和葡萄糖-胰岛素特征的影响。

研究设计和方法:我们利用了来自Healthy Start的103对母子子样本,这是一个基于科罗拉多州的多种族队列。在孕27周的孕妇尿液中检测了12种大麻素/大麻代谢物(包括δ9-四氢大麻酚和大麻二酚)。胎儿对大麻的暴露分为暴露(任何大麻素>检测限[LOD])和未暴露(所有大麻素< LOD)。在随访时(平均年龄:4.7岁),通过空气置换体积描记法测量脂肪质量和无脂肪质量。隔夜禁食后获得葡萄糖和胰岛素。广义线性模型估计了胎儿接触大麻与肥胖指标(脂肪质量[kg]、无脂肪质量[kg]、肥胖[脂肪质量百分比]、体重指数[身体质量指数]和身体质量指数z评分)和代谢指标(葡萄糖[mg/dL]、胰岛素[uIU/mL]和胰岛素抵抗稳态模型评估[HOMA-IR])之间的关联。

结果:大约15%的妇女有任何大麻素的可检测水平,表明胎儿暴露于大麻。暴露的后代脂肪量较高(1 . 0kg;95% CI,0.3-1 .7),去脂质量(1 . 2kg;95% CI,0.4-2.0),肥胖(2.6%;95% CI,0.1-5.2),以及空腹血糖(5.6mg/dL;95%可信区间,0.8-10.3)。没有发现与空腹胰岛素(在完全调整的模型中)、HOMA胰岛素抵抗指数、身体质量指数或身体质量指数z评分有关联。

表1 健康之星的103名合格参与者中12种大麻素和大麻素代谢物的尿液浓度和简要描述(ng/mL)

表2 健康起点的胎儿大麻暴露和儿童期肥胖,n = 103

表3健康开始时胎儿接触大麻和儿童期代谢结果,n = 88

结论:我们提供了新的证据,表明胎儿暴露于大麻与儿童期肥胖和空腹血糖增加有关,这一发现应该在其他队列中得到验证。

原文出处: Moore BF,  Sauder KA,  Shapiro ALB, et al.Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study.J Clin Endocrinol Metab 2022 Mar 31

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063619, encodeId=5fa620636199b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 04 16:56:17 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778237, encodeId=07fe1e782379a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 10 13:56:17 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219951, encodeId=cea01219951d2, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:43:33 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272796, encodeId=5d3412e2796ab, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Apr 29 01:56:17 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-10-04 docwu2019
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063619, encodeId=5fa620636199b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 04 16:56:17 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778237, encodeId=07fe1e782379a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 10 13:56:17 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219951, encodeId=cea01219951d2, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:43:33 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272796, encodeId=5d3412e2796ab, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Apr 29 01:56:17 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2023-01-10 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063619, encodeId=5fa620636199b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 04 16:56:17 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778237, encodeId=07fe1e782379a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 10 13:56:17 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219951, encodeId=cea01219951d2, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:43:33 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272796, encodeId=5d3412e2796ab, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Apr 29 01:56:17 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-05-16 赛华佗
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063619, encodeId=5fa620636199b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 04 16:56:17 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778237, encodeId=07fe1e782379a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 10 13:56:17 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219951, encodeId=cea01219951d2, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:43:33 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272796, encodeId=5d3412e2796ab, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Apr 29 01:56:17 CST 2022, time=2022-04-29, status=1, ipAttribution=)]
    2022-04-29 kcb069

相关资讯

FDA批准**疗法治疗致命儿童代谢缺陷

美国FDA批准了Origin Biosciences的新药Nulibry(fosdenopterin)上市,用于降低因A型钼辅因子缺乏(MoCD)导致的死亡风险。FDA药物评估和研究中心罕见病、儿科、